Physician profile
Padma Chamarthy
NPI 1316397425
$3,389.95
in general payments reported to CMS, 2019-2025
22 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $519 · 2023: $403 · 2024: $754 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.99 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,317.47 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $234.49 | 2024-2025 | |
| Lilly USA, LLC | $227.88 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $227.29 | 2023-2025 | Dupixent |
| Abbvie INC. | $188.72 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $176.27 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $172.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $150.44 | 2022-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $127.32 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $96.49 | 2022 | |
| Medtronic, INC. | $86.25 | 2025 | Interstim |
| Redhill Biopharma INC. | $64.42 | 2021-2023 | |
| Braintree Laboratories, INC. | $49.47 | 2021-2023 | Suflave |
| Celgene Corporation | $41.03 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $40.21 | 2024 | Watchman |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $37.57 | 2024-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $37.01 | 2025 | Wegovy |
| Pfizer INC. | $33.42 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $30.48 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $22.09 | 2024 | Rebyota |
| Ge Healthcare | $16.82 | 2025 | |
| Merck Sharp & Dohme LLC | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Chamarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.